Clinical trials
Full profile accessFollow clinical development from trial design and recruitment through results.
- Trial phase
- Status
- Readouts
Company intelligence / Profile preview
Redhill Capital
Tel Aviv, Israel
- Ownership
- Private
- Employees
- ~35
- Development stage
- Other
01
Overview
RedHill Biopharma has FDA-approved commercial products Talicia (H. pylori), Aemcolo (travelers’ diarrhea), and Movantik (opioid-induced constipation) generating revenue. Pipeline includes late-stage programs like opaganib (Phase 2 in mCRPC) and RHB-204 (planned Phase 2 in MAP-positive Crohn's disease).[1][2][4]
- Therapeutic areas
- OncologyInfectious DiseasesGastroenterology
- Modalities
- Small molecule
- Industry
- Biotech
02
Partnerships
Bayer (opaganib Phase 2 study)Hyloris Pharma (RHB-102 out-licensing, up to $60M)U.S. Government (pandemic preparedness)
Beyond the preview
Go deeper on Redhill Capital.
Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.
Licensing & deals
Full profile accessExplore licensing agreements, acquisitions, and the assets behind each deal.
- Partners
- Deal terms
- Milestones
Funding history
Full profile accessTrace financing activity and the investors behind a company’s development.
- Funding rounds
- Investors
- Capital raised
Competitive landscape
Full profile accessCompare peer pipelines by target, modality, and therapeutic area.
- Peer companies
- Targets
- Pipeline overlap
Technologies & patents
Full profile accessExplore technology platforms and the patent landscape around relevant assets.
- Platforms
- Patents
- Assignees
Research & analysis
Full profile accessConnect company news and source material to the questions you’re investigating.
- Company news
- Sources
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on Redhill Capital.